Today, COMPASS Pathways announced pricing of a private placement financing for up to $285 million with leading healthcare investors, with approximately $125 million in gross proceeds at closing and up to an additional approximately $160 million if the warrants are fully exercised with cash. Kabir Nath, CEO of COMPASS Pathways said, “We are grateful for the support of this group of sophisticated healthcare investors for our work to bring potentially transformative treatment for mental health conditions to patients urgently in need of better options. We thank these investors for their confidence in our rigorous approach to building a strong base of evidence for the potential of COMP360 psilocybin treatment to help people with treatment-resistant depression, post-traumatic stress disorder and anorexia nervosa. These funds will allow us to advance our pivotal phase 3 program in TRD and achieve important milestones in the development of COMP360. We view this investment as a validation of the potential of psychedelic medicine and the importance of a rigorous and evidence-based approach.” https://lnkd.in/e-kmhRNA
It's so inspiring to see we're making movements with psychedelic medicine! Can't wait to read the results!
Very good news
Congrats team COMPASS Pathways on achieving this incredible milestone! 👏
Amazing news, excited!
Congratulations, COMPASS Pathways!
Congratulations COMPASS Pathways!
Congratulations George and the team at Compass Pathways.
Congratulations all
Congrats Matthew Owens
Investing in bio and healthcare
1ywhat a great investor list! this brings a lot of legitimacy to psychedelics